Vifor Pharma (GNHAF) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free GNHAF Stock Alerts $181.25 0.00 (0.00%) (As of 10/21/2022) Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVifor Pharma offers to rectify anti-competitive behaviour against rivalyahoo.com - April 19 at 10:57 AMVifor Pharma offers to fix alleged anti-competitive behaviourmsn.com - April 19 at 10:57 AMKapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusfinance.yahoo.com - May 21 at 3:50 PMVifor Pharma AG (VIFNE)uk.investing.com - May 10 at 5:54 PMCancellation of remaining publicly held registered shares of Vifor Pharma AGfinancialpost.com - December 14 at 1:15 AMCancellation of remaining publicly held registered shares of Vifor Pharma AGfinancialpost.com - December 14 at 1:15 AMApproval of extension of exemptions from SIX disclosure and publicity obligationsfinance.yahoo.com - October 20 at 2:17 AMAustralia’s CSL raises annual profit forecast on Swiss acquisitionfinancialpost.com - October 16 at 11:07 PMApproval of delisting of Vifor Pharma AG’s registered sharesfinancialpost.com - October 12 at 1:27 AMCSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathyfinance.yahoo.com - August 22 at 11:01 AMVFMCRP announces U.S. Court upholds validity of Velphoro® patentfinance.yahoo.com - August 22 at 1:35 AMVifor Fresenius : England's NICE Recommends Tavneos For Treatment Of ANCA-associated Vasculitismarkets.businessinsider.com - August 18 at 1:31 AMTavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)finance.yahoo.com - August 18 at 1:31 AMExtension of the postponement of the settlement of Vifor Pharma tender offerfinance.yahoo.com - July 13 at 2:09 AMAkebia Therapeutics Amends License Agreement with Viformorningstar.com - February 23 at 7:28 AMAkebia amends license agreement with Vifor for potential launch of kidney drugseekingalpha.com - February 23 at 7:28 AMVifor Pharma reports sustained growth in 2021finance.yahoo.com - February 17 at 5:17 AMVifor Pharma AG Registered Shares (GNHAF)nasdaq.com - January 13 at 10:25 PMChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA Nodfinance.yahoo.com - December 27 at 9:06 AMVifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®finance.yahoo.com - December 21 at 9:50 AMVifor Pharma Settles Patent Litigations Regarding Injectafer - Quick Factsnasdaq.com - December 20 at 8:58 AMVifor Pharma and American Regent announce settlement of Injectafer® patent litigationfinance.yahoo.com - December 20 at 1:06 AMVifor Pharma Divests Finished Drug Product Manufacturing Business To CordenPharmanasdaq.com - December 16 at 9:23 AMAustralia’s CSL to Buy Drugmaker Vifor for $11.7 Billionfinance.yahoo.com - December 14 at 9:10 AMAustralia’s CSL to buy Swiss drugmaker Vifor for $11.7 blnfinancialpost.com - December 14 at 2:29 AMVifor Pharma comments on media speculationfinance.yahoo.com - December 13 at 9:42 AMUPDATE 1-European shares gain ahead of big week for central banksfinance.yahoo.com - December 13 at 9:42 AMVifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injuryfinance.yahoo.com - December 10 at 5:33 AMVifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committeefinance.yahoo.com - December 10 at 5:33 AMAngion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injuryfinance.yahoo.com - December 9 at 5:37 PMVifor Pharma comments on market speculationsfinance.yahoo.com - December 2 at 1:29 PMVifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosisfinance.yahoo.com - November 26 at 1:11 AMVifor Pharma Bolsters Its Presence In Vascular Calcification Field Via Two Acquisition Dealsfinance.yahoo.com - November 22 at 2:36 PMVFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitisfinance.yahoo.com - November 12 at 1:56 AMVifor Pharma and Angion report topline results...benzinga.com - October 29 at 12:41 AMVifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft functionfinance.yahoo.com - October 27 at 2:09 AMVFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japanfinance.yahoo.com - September 27 at 3:49 AMVifor Pharma's Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelinesbenzinga.com - August 31 at 12:59 PMVifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelinesfinance.yahoo.com - August 31 at 1:35 AMWhy Cara Therapeutics Shot Higher Todayfinance.yahoo.com - August 24 at 5:01 PMSee Why Cara Therapeutics (CARA) Stock Is Moving Higher On Tuesdayfeeds.benzinga.com - August 24 at 8:14 AMCara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patientsfinance.yahoo.com - August 23 at 5:25 PMCara Therapeutics, inc (CARA) Q2 2021 Earnings Call Transcriptfinance.yahoo.com - August 17 at 2:21 AMVifor Pharma AG (VIFN)investing.com - August 11 at 8:41 AM Get Vifor Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GNHAF and its competitors with MarketBeat's FREE daily newsletter. Email Address The Hard Truth About Investing For Retirement (Ad)Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading. Click To Access This Powerful Training Right Now! GNHAF Media Mentions By Week GNHAF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNHAF News Sentiment▼0.000.44▲Average Medical News Sentiment GNHAF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNHAF Articles This Week▼20▲GNHAF Articles Average Week Get Vifor Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GNHAF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TGIFF News FFNTF News ABSCF News ACRDF News ACRHF News ALEAF News LBTSF News AZFL News ERBB News AVTBF News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:GNHAF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry"The Biggest Drug Ever" Is ComingBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vifor Pharma AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
